Table 3.
Pathway | # Biomarkers in cluster/Total # of biomarkers in pathway (Reactome) | p | pFDR-corrected a | Biomarkers |
---|---|---|---|---|
Inflammation pathways | ||||
Interleukin-4 and Interleukin-13 signaling | 2/211 | <0.001 | <0.001 | MMP3, MMP3 |
Neutrophil degranulation | 4/480 | <0.001 | 0.008 | MMP9, CTSD, CSTB, PECAM1 |
Senescence-Associated Secretory Phenotype | 1/91 | 0.005 | 0.038 | IGFBP7 |
Extracellular matrix organization pathways | ||||
Degradation of the extracellular matrix | 4/148 | <0.001 | 0.001 | MMP9, CTSD, MMP3, HSPG2 |
Extracellular matrix organization | 5/301 | <0.001 | 0.001 | MMP9, CTSD, PECAM1, MMP3, HSPG2 |
Collagen degradation | 3/64 | <0.001 | 0.002 | MMP9, CTSD, MMP3 |
Activation of Matrix Metalloproteinases | 2/33 | 0.001 | 0.015 | MMP9, MMP3 |
Assembly of collagen fibrils and other multimeric structures | 2/61 | 0.003 | 0.030 | MMP9, MMP3 |
Collagen formation | 2/90 | 0.007 | 0.036 | MMP9, MMP3 |
Integrin cell surface interactions | 2/85 | 0.006 | 0.036 | PECAM1, HSPG2 |
Signal transduction pathways | ||||
ESR-mediated signaling | 3/196 | 0.003 | 0.028 | MMP9, CTSD, MMP3 |
Signaling by Interleukins | 4/457 | 0.003 | 0.030 | MMP9, MMP3 |
Signaling by Nuclear Receptors | 3/273 | 0.006 | 0.036 | MMP9, CTSD, MMP3 |
Extra-nuclear estrogen signaling | 2/80 | 0.006 | 0.036 | MMP9, MMP3 |
Transport of small molecules pathway | ||||
Intracellular oxygen transport | 1/5 | 0.006 | 0.038 | MB |
False Discovery Rate-corrected p-values
The number of biomarkers involved in the cluster and belonging to the pathway are shown, as a ratio to the known total number of biomarkers involved in the pathway based on the Reactome pathway analysis tool. For example, 480 proteins are known to be involved in Neutrophil degranulation, of which four are part of our 13-component cluster (MMP9, CTSD, CSTB, PECAM1), this pathway is significantly enriched (pFDR-corrected < 0.001).